- Home
- UNCY vs CVM Comparison
UNCY vs CVM Comparison
Compare UNCY & CVM Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- UNCY
- CVM
- Stock Information
- Founded
- UNCY 2016
- CVM 1983
- Country
- UNCY United States
- CVM United States
- Employees
- UNCY N/A
- CVM N/A
- Industry
- UNCY Biotechnology: Pharmaceutical Preparations
- CVM Biotechnology: Biological Products (No Diagnostic Substances)
- Sector
- UNCY Health Care
- CVM Health Care
- Exchange
- UNCY Nasdaq
- CVM Nasdaq
- Market Cap
- UNCY 74.2M
- CVM 71.8M
- IPO Year
- UNCY 2021
- CVM 1987
- Fundamental
- Price
- UNCY $4.36
- CVM $10.47
- Analyst Decision
- UNCY Strong Buy
- CVM
- Analyst Count
- UNCY 4
- CVM 0
- Target Price
- UNCY $63.75
- CVM N/A
- AVG Volume (30 Days)
- UNCY 483.3K
- CVM 328.8K
- Earning Date
- UNCY 08-14-2025
- CVM 08-14-2025
- Dividend Yield
- UNCY N/A
- CVM N/A
- EPS Growth
- UNCY N/A
- CVM N/A
- EPS
- UNCY N/A
- CVM N/A
- Revenue
- UNCY N/A
- CVM N/A
- Revenue This Year
- UNCY N/A
- CVM N/A
- Revenue Next Year
- UNCY $3,131.28
- CVM N/A
- P/E Ratio
- UNCY N/A
- CVM N/A
- Revenue Growth
- UNCY N/A
- CVM N/A
- 52 Week Low
- UNCY $3.24
- CVM $1.98
- 52 Week High
- UNCY $11.00
- CVM $39.30
- Technical
- Relative Strength Index (RSI)
- UNCY 49.39
- CVM 55.16
- Support Level
- UNCY $4.15
- CVM $8.65
- Resistance Level
- UNCY $4.35
- CVM $12.68
- Average True Range (ATR)
- UNCY 0.24
- CVM 1.28
- MACD
- UNCY 0.05
- CVM -0.03
- Stochastic Oscillator
- UNCY 53.76
- CVM 44.67
About UNCY Unicycive Therapeutics Inc.
Unicycive Therapeutics Inc is a biotechnology company dedicated to developing treatments for certain medical conditions. It is focusing on kidney diseases. The company's manufactures drug, Renazorb, is a novel phosphate-binding agent being developed for the treatment of hyperphosphatemia. Unicycive's other drug, UNI-494, is a new chemical entity with the issued composition of matter patent protection in late preclinical development for the treatment of acute kidney injury. Company's pipeline comprised of two product candidates: Oxylanthanum Carbonate and UNI-494.
About CVM Cel-Sci Corporation
CEL-SCI Corp is a player in the biotechnology sector. It is engaged in the research and development of the treatment of cancer and other diseases using the immune system. The Company's core capabilities include drug discovery, research, development, and manufacturing of complex biological substances. It is focused on the development of Multikine (Leukocyte Interleukin, Injection), investigational immunotherapy under development for the treatment of certain head and neck cancers, and anal warts or cervical dysplasia.